Stability, speed and strategy: Inside Australia’s early‑stage edge
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Jerome Barley, Commercial Director, Avion Medical
Ryan Klein, Vice President, Business Development, US and APAC, Resolian
Disclaimer: The views expressed in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.